Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin added to insulin in Type 2 Diabetes
NCT00673231Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2008
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Apr 2008; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00673231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00673231.